Phase I
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
This morning, the Indianapolis-based company said it will delay most new study starts and pause enrollment in most ongoing studies in light of the COVID-19 pandemic.
A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
Researchers found fear of testing new treatments and possible side effects were common denominators among patients.
As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.
The company disclosed that the U.S. Food and Drug Administration placed a partial clinical hold on its Phase I trial for non-Hodgkin lymphoma due to a safety concern.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
PRESS RELEASES